<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T09:27:17Z</responseDate>
  <request identifier="oai:figshare.com:article/30537245" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/30537245</identifier>
        <datestamp>2026-09-29T07:37:36Z</datestamp>
        <setSpec>category_24094</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;b&gt;Antimicrobial peptide PMAP-36 attenuates ExPEC-induced neuroinflammation by inhibiting the NF-&lt;/b&gt;&lt;b&gt;κ&lt;/b&gt;&lt;b&gt;B/NLRP3 pathway through autophagy activation&lt;/b&gt;</dc:title>
          <dc:creator>Lianci Peng (22561466)</dc:creator>
          <dc:subject>Veterinary immunology</dc:subject>
          <dc:subject>PMAP-36</dc:subject>
          <dc:subject>extraintestinal pathogenic E. coli</dc:subject>
          <dc:subject>anti-neuroinflammation</dc:subject>
          <dc:subject>autophagy activation</dc:subject>
          <dc:subject>Anti-inflammatory response</dc:subject>
          <dc:description>&lt;p dir="ltr"&gt;&lt;b&gt;Supplementary materials&lt;/b&gt;&lt;/p&gt;&lt;p dir="ltr"&gt;&lt;b&gt;Figure S1. The biocompatible effect of PMAP-36 in vitro and in vivo&lt;/b&gt;. (A) The viability of BV2 cells treated with PMAP-36 (0.625 μM or 1.25 μM) for 12 h, followed by washing and then incubation for an additional 24 h, was detected via the CCK-8 assay. Mice (total N=18) were intraperitoneally injected with 5 mg/kg PMAP-36 or PBS as a negative control. (B) Body weight was monitored daily for 7 d, and variations in body weights (%) (total N=12, per group n=6) are shown. (C-F) Blood was collected to determine biochemical indicators, including alanine aminotransferase (ALT) (C), aspartate aminotransferase (AST) (D), urea (UREA) (E) and inorganic phosphate (IP) (F). Different tissues (total N=6, per group n=3), including the brain, lung, liver, and spleen, were collected to observe histopathological changes. (G) Representative images of histopathological changes in tissues are shown. All data are presented as the means ± SEM from five, six, or three biological replicates. ns = not significant.&lt;/p&gt;&lt;p dir="ltr"&gt;&lt;b&gt;Figure S2. The effect of PMAP-36 on bacterial invasion in BV2 cells&lt;/b&gt;. (A) The number of intracellular bacteria in ExPEC-infected BV2 cells with PMAP-36 treatment under the condition of 3-MA and CQ at 1 and 2 h post infection. Data are presented as the means ± SEM from three biological replicates. ***&lt;i&gt;P&lt;/i&gt; ≤ 0.001, ns = not significant.&lt;/p&gt;</dc:description>
          <dc:date>2025-11-05T03:39:57Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.6084/m9.figshare.30537245.v9</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_b_Antimicrobial_peptide_PMAP-36_attenuates_ExPEC-induced_neuroinflammation_by_inhibiting_the_NF-_b_b_b_b_B_NLRP3_pathway_through_autophagy_activation_b_/30537245</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
